NCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
Clinical Trials
264 trialsNCT05923060 2026-02-20
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT05662202 2026-02-19
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT07286318 2026-02-19
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients
University of Pittsburgh
Phase EARLY_PHASE1 Not yet recruiting
NCT07401277 2026-02-10
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
West Virginia University
Phase 1 Not yet recruiting
NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
NCT05212246 2026-01-22
B3C
VA Office of Research and Development
Phase 3 Not yet recruiting
NCT06135415 2026-01-22
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT07335003 2026-01-12
Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses
Cosmetique Active International
Phase NA Recruiting
NCT07318675 2026-01-06
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1 Recruiting
NCT07053852 2026-01-02
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
Rochester Dermatologic Surgery
Phase 1 Completed
NCT06778434 2025-12-22
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
VA Office of Research and Development
Phase 2 Recruiting
NCT07290959 2025-12-18
Indoor Daylight Photodynamic Therapy is an Effective, First-line Treatment for AK, But Its Feasibility is Limited by the Time Required for the Illumination (2 Hours). Our Objective Was to Evaluate the Efficacy of Idl-PDT With an Illumination Time of 1 Hour Versus 2 Hours in the Treatment of Scalp AK
San Salvatore Hospital of L'Aquila
Phase NA Completed
NCT07273656 2025-12-09
TIRBACRYO
University Hospital, Lille
Phase 3 Not yet recruiting
NCT06461442 2025-12-05
Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis
University of California, Davis
Phase 4 Enrolling by invitation
NCT06027619 2025-10-23
Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05699603 2025-09-24
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
University of Arizona
Phase 2 Active not recruiting
NCT07049068 2025-09-15
Comparison of Nicotinamide Treatments for Actinic Keratosis
Federal University of Rio Grande do Sul
Phase 1 Completed
NCT07137819 2025-08-22
EXACT-1
Aresus Pharma GmbH
Phase 3 Recruiting
NCT06319794 2025-07-18
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
TORQUR
Phase 2 Completed
NCT06499415 2025-05-11
CALM
Maastricht University Medical Center
Phase 4 Recruiting
NCT04429308 2025-05-08
PDT vs Peels for Treatment of Actinic Keratoses
Northwestern University
Phase 2 Not yet recruiting
NCT04329221 2025-05-07
Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT04642287 2025-05-07
Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients
Massachusetts General Hospital
Phase 2 Withdrawn
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT06008171 2025-04-04
Patient Decision Aid for the Treatment of Actinic Keratosis
Maastricht University Medical Center
Phase NA Active not recruiting
NCT03906253 2025-03-25
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
Wright State University
Phase NA Recruiting
NCT01820260 2025-03-13
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02549352 2025-03-13
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT03115476 2025-03-11
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
LEO Pharma
Phase 3 Terminated
NCT01541553 2025-03-10
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT02547233 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02547363 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02549339 2025-03-10
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT01922050 2025-03-06
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02100813 2025-03-06
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02120456 2025-03-06
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT01387711 2025-02-24
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
LEO Pharma
Phase 1 Completed
NCT01703078 2025-02-24
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
LEO Pharma
Phase 1 Completed
NCT01787383 2025-02-24
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
LEO Pharma
Phase 3 Completed
NCT01892137 2025-02-24
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
LEO Pharma
Phase 1 Completed
NCT02124239 2025-02-24
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
LEO Pharma
Phase 1 Completed
NCT02406014 2025-02-24
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
LEO Pharma
Phase 4 Completed
NCT02424305 2025-02-24
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
LEO Pharma
Phase 1 Completed